Nawar Latif
YOU?
Author Swipe
View article: A Call To Action: Developing an Agile Global Regulatory Affairs Workforce for the Future
A Call To Action: Developing an Agile Global Regulatory Affairs Workforce for the Future Open
View article: Ovarian carcinoid tumor with carcinoid heart syndrome: A case report and literature review
Ovarian carcinoid tumor with carcinoid heart syndrome: A case report and literature review Open
View article: Supplemental Figure S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Supplemental Figure S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study Open
Time between [18F]FTT imaging scans did not significantly impact SUV measurements.
View article: Supplemental Figure S3 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Supplemental Figure S3 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study Open
Anatomic imaging corelates.
View article: Supplemental Figure S4 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Supplemental Figure S4 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study Open
Baseline [18F]FTT imaging correlates.
View article: Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer Open
Trial schema
View article: Supplemental Figure S6 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Supplemental Figure S6 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study Open
18F]FTT-PET on subject previously treated with PARPi.
View article: Supplemental Figure S1 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Supplemental Figure S1 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study Open
PDX models treated with PARPi therapies.
View article: Supplemental Table S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Supplemental Table S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study Open
PARPi treatment and response.
View article: Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer Open
Representativeness of Study Participants
View article: Assessing Community Knowledge and Attitudes on Cardiopulmonary Resuscitation and Automated External Defibrillator in Ipoh, Perak
Assessing Community Knowledge and Attitudes on Cardiopulmonary Resuscitation and Automated External Defibrillator in Ipoh, Perak Open
Introduction: Cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) use are critical interventions for out-of-hospital cardiac arrest (OHCA), significantly improving survival rates. This study assessed the knowledg…
View article: Outcomes of patients with metastatic squamous cell carcinoma of the vulva
Outcomes of patients with metastatic squamous cell carcinoma of the vulva Open
Stage IVB vulvar carcinoma has a poor prognosis. Patients with distant lymph node involvement have a better prognosis than those with other distant metastases, especially when multi-modal treatment is used. The efficacy of multi-agent chem…
View article: Outcomes of the sentinel lymph node mapping algorithm for patients with locally advanced endometrial carcinoma
Outcomes of the sentinel lymph node mapping algorithm for patients with locally advanced endometrial carcinoma Open
Patients with locally advanced endometrial cancer have a high incidence of lymph node metastases. For these patients, sentinel lymph node biopsy is associated with overall survival similar to that of systematic lymphadenectomy.
View article: Feasibility of Near-Infrared Spectroscopy for Monitoring Tissue Oxygenation During Uterus Transplantation and Hysterectomy
Feasibility of Near-Infrared Spectroscopy for Monitoring Tissue Oxygenation During Uterus Transplantation and Hysterectomy Open
Background/Objective: Thrombosis is the leading cause of graft failure and immediate hysterectomy following uterus transplantation (UTx). Currently, there is no standardized method for real-time assessment of UTx graft perfusion. This feas…
View article: Social Isolation among Ageing Population in Malaysia
Social Isolation among Ageing Population in Malaysia Open
View article: Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Representativeness of Study Participants
View article: Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial protocol
View article: Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial schema
View article: Data from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Data from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Purpose: Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to poly-ADP ribose polymerase inhibitors (PARPi) overcomes PARPi-resistance in high grade serous ovarian cancer (HGSOC) cell and mouse models. We present …
View article: Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial protocol
View article: Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Representativeness of Study Participants
View article: Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial schema
View article: Outcomes of Radical Hysterectomy for Early-Stage Cervical Carcinoma, with or without Prior Cervical Excision Procedure
Outcomes of Radical Hysterectomy for Early-Stage Cervical Carcinoma, with or without Prior Cervical Excision Procedure Open
Objective: To investigate the impact of a prior cervical excisional procedure on the oncologic outcomes of patients with apparent early-stage cervical carcinoma undergoing radical hysterectomy. Methods: The National Cancer Database (2004–2…
View article: Availability of Deceased Donors for Uterus Transplantation in the United States: Perception vs. Reality
Availability of Deceased Donors for Uterus Transplantation in the United States: Perception vs. Reality Open
Uterus transplantation (UTx) is a rapidly evolving treatment for uterine factor infertility. New centers offering this treatment must decide whether to utilize living donors, deceased donors, or both. Although limiting UTx to deceased dono…
View article: EP292/#701 Revisiting the role of interval cytoreductive surgery (ICS) following neoadjuvant chemotherapy (NACT) for patients with advanced stage epithelial ovarian cancer; a multicenter database analysis
EP292/#701 Revisiting the role of interval cytoreductive surgery (ICS) following neoadjuvant chemotherapy (NACT) for patients with advanced stage epithelial ovarian cancer; a multicenter database analysis Open
Introduction Investigate the role ICS for ovarian cancer patients receiving NACT. Methods Patients diagnosed between 2010–2015 with stage III-IV ovarian carcinoma who received NACT and ICS with known status of residual disease were identif…
View article: SO009/#656 Utilization and outcomes of sentinel lymph node biopsy (SLNBX) for patients with cervical carcinoma; a multicenter database analysis
SO009/#656 Utilization and outcomes of sentinel lymph node biopsy (SLNBX) for patients with cervical carcinoma; a multicenter database analysis Open
Introduction Investigate the utilization and outcomes of SLNBx algorithm for patients with cervical carcinoma. Methods Patients diagnosed between 2012–2019 with cervical carcinoma who underwent hysterectomy with SLNBx or systematic lymphad…
View article: Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery
Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery Open
View article: Molecular profiling of mucinous ovarian carcinoma reveals actionable mutations and a unique genomic profile (1282)
Molecular profiling of mucinous ovarian carcinoma reveals actionable mutations and a unique genomic profile (1282) Open
View article: Just text me: A feasibility study of texting evaluations for gynecologic oncology patients undergoing chemotherapy (2199)
Just text me: A feasibility study of texting evaluations for gynecologic oncology patients undergoing chemotherapy (2199) Open
View article: Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer Open
Trial schema